

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

## Drug Advisory Committee Jan 2021 Meeting Outcome

Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
Arsenic Trioxide	Arsenol	Malignant disease and immunosuppression	Approved	
Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
Baloxavir	Xofluza	Infections	Rejected	Alternative(s) available in HADF with comparable benefits
Bilastine	Labixten	Respiratory system	Rejected	Alternative(s) available in HADF with comparable benefits
Brexpiprazole	Rexulti	Central nervous system	Approved	
Brodalumab	Lumicef	Skin	Rejected	Alternative(s) available in HADF with comparable benefits
Cladribine	Mavenclad	Malignant disease and immunosuppression	Approved	
Dacomitinib	Vizimpro	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
Emicizumab	Hemlibra	Cardiovascular system	Approved	
Entrectinib	Rozlytrek	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
Fentanyl citrate	PecFent	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
Gemtuzumab Ozogamicin	Mylotarg	Malignant disease and immunosuppression	Pending	Pending further information
Lisdexamfetamine	Vyvanse	Central nervous system	Approved	
Niraparib	Zejula	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
Polatuzumab vedotin	Polivy	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
Ranibizumab	Lucentis	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
Rituximab	Rixathon	Malignant disease and immunosuppression	Approved	
Sirolimus	Rapamune	Malignant disease and immunosuppression	Approved	
Tisagenlecleucel	Kymriah	Malignant disease and immunosuppression	Approved	
	Arsenic Trioxide Atezolizumab Baloxavir Bilastine Brexpiprazole Brodalumab Cladribine Dacomitinib Emicizumab Entrectinib Fentanyl citrate Gemtuzumab Ozogamicin Lisdexamfetamine Niraparib Polatuzumab vedotin Ranibizumab Rituximab Sirolimus	Arsenic TrioxideArsenolAtezolizumabTecentriqBaloxavirXofluzaBilastineLabixtenBrexpiprazoleRexultiBrodalumabLumicefCladribineMavencladDacomitinibVizimproEmicizumabHemlibraEntrectinibRozlytrekFentanyl citratePecFentGemtuzumab OzogamicinMylotargLisdexamfetamineVyvanseNiraparibZejulaPolatuzumab vedotinPolivyRanibizumabRixathonSirolimusRapamune	Arsenic TrioxideArsenolMalignant disease and immunosuppressionAtezolizumabTecentriqMalignant disease and immunosuppressionBaloxavirXofluzaInfectionsBilastineLabixtenRespiratory systemBrexpiprazoleRexultiCentral nervous systemBrodalumabLumicefSkinCladribineMavencladMalignant disease and immunosuppressionDacomitinibVizimproMalignant disease and immunosuppressionEmicizumabHemlibraCardiovascular systemEntrectinibRozlytrekMalignant disease and immunosuppressionFentanyl citratePecFentCentral nervous systemGemtuzumab OzogamicinMylotargMalignant disease and immunosuppressionLisdexamfetamineVyvanseCentral nervous systemNiraparibZejulaMalignant disease and immunosuppressionPolatuzumab vedotinPolivyMalignant disease and immunosuppressionRituximabLucentisEyeRituximabRixathonMalignant disease and immunosuppression	Generic nameBrand nameTherapetitic ClassoutcomeArsenic TrioxideArsenolMalignant disease and immunosuppressionApprovedAtezolizumabTecentriqMalignant disease and immunosuppressionRejectedBaloxavirXofluzaInfectionsRejectedBilastineLabixtenRespiratory systemRejectedBrodalumabLumicefSkinRejectedCladribineMavencladMalignant disease and immunosuppressionApprovedDacomitinibVizimproMalignant disease and immunosuppressionApprovedEmicizumabHemlibraCardiovascular systemApprovedEntrectinibRozlytrekMalignant disease and immunosuppressionRejectedEditationeVizimproMalignant disease and immunosuppressionRejectedEntrectinibRozlytrekMalignant disease and immunosuppressionRejectedEntrectinibRozlytrekMalignant disease and immunosuppressionRejectedFentanyl citratePecFentCentral nervous systemApprovedNiraparibZejulaMalignant disease and immunosuppressionRejectedPolatuzumab vedotinPolivyMalignant disease and immunosuppressionRejectedRanibizumabLucentisEyeRejectedRanibizumabRixathonMalignant disease and immunosuppressionApprovedApprovedRixathonMalignant disease and immunosuppressionApprovedRolatuzumabRixathonMalignant disease and immunosuppressionApproved

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
20	Tocilizumab	Actemra	Musculoskeletal and joint disease	Approved	
21	Trastuzumab	Herzuma	Malignant disease and immunosuppression	Approved	

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.